Simulations Plus, Inc. (SLP)

$44.41

-0.29

(-0.65%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Simulations Plus, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 14.5M → 18.30M (in $), with an average increase of 20.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 534.0K → 4.02M (in $), with an average increase of 62.1% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 37.0% return, outperforming this stock by 31.6%

  • Vs HQY

    In the last 3 years, Healthequity Inc has given 12.5% return, outperforming this stock by 41.4%

Performance

  • $44.20
    $45.55
    $44.41
    downward going graph

    0.47%

    Downside

    Day's Volatility :2.96%

    Upside

    2.5%

    downward going graph
  • $32.59
    $52.34
    $44.41
    downward going graph

    26.62%

    Downside

    52 Weeks Volatility :37.73%

    Upside

    15.15%

    downward going graph

Returns

PeriodSimulations Plus, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
17.85%
-0.7%
0.0%
6 Months
13.39%
6.6%
0.0%
1 Year
5.42%
3.7%
-1.5%
3 Years
-28.49%
14.0%
-21.8%

Highlights

Market Capitalization
906.5M
Book Value
$8.86
Dividend Share
0.24
Dividend Yield
0.53%
Earnings Per Share (EPS)
0.52
PE Ratio
87.23
PEG Ratio
9.77
Wall Street Target Price
53.67
Profit Margin
16.26%
Operating Margin TTM
24.27%
Return On Assets TTM
4.43%
Return On Equity TTM
6.16%
Revenue TTM
64.7M
Revenue Per Share TTM
3.24
Quarterly Revenue Growth YOY
16.2%
Gross Profit TTM
43.1M
EBITDA
15.7M
Diluted Eps TTM
0.52
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.66
EPS Estimate Next Year
0.8
EPS Estimate Current Quarter
0.19
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Simulations Plus, Inc.(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 20.85%

Current $44.41
Target $53.67

Company Financials

FY18Y/Y Change
Revenue
29.7M
↑ 22.9%
Net Income
8.9M
↑ 54.38%
Net Profit Margin
30.12%
↑ 6.14%
FY19Y/Y Change
Revenue
34.0M
↑ 14.51%
Net Income
8.6M
↓ 3.93%
Net Profit Margin
25.27%
↓ 4.85%
FY20Y/Y Change
Revenue
41.6M
↑ 22.43%
Net Income
9.3M
↑ 8.72%
Net Profit Margin
22.44%
↓ 2.83%
FY21Y/Y Change
Revenue
46.5M
↑ 11.73%
Net Income
9.8M
↑ 4.82%
Net Profit Margin
21.05%
↓ 1.39%
FY22Y/Y Change
Revenue
53.9M
↑ 16.01%
Net Income
12.5M
↑ 27.61%
Net Profit Margin
23.16%
↑ 2.11%
FY23Y/Y Change
Revenue
59.6M
↑ 10.52%
Net Income
10.0M
↓ 20.2%
Net Profit Margin
16.72%
↓ 6.44%
Q4 FY22Q/Q Change
Revenue
12.0M
↑ 1.96%
Net Income
1.2M
↑ 29.55%
Net Profit Margin
10.41%
↑ 2.22%
Q1 FY23Q/Q Change
Revenue
15.8M
↑ 31.64%
Net Income
4.2M
↑ 235.26%
Net Profit Margin
26.5%
↑ 16.09%
Q2 FY23Q/Q Change
Revenue
16.2M
↑ 3.07%
Net Income
4.0M
↓ 3.98%
Net Profit Margin
24.69%
↓ 1.81%
Q3 FY23Q/Q Change
Revenue
15.6M
↓ 3.73%
Net Income
534.0K
↓ 86.68%
Net Profit Margin
3.42%
↓ 21.27%
Q4 FY23Q/Q Change
Revenue
14.5M
↓ 7.22%
Net Income
1.9M
↑ 264.23%
Net Profit Margin
13.41%
↑ 9.99%
Q1 FY24Q/Q Change
Revenue
18.3M
↑ 26.24%
Net Income
4.0M
↑ 107.15%
Net Profit Margin
22.01%
↑ 8.6%
FY18Y/Y Change
Total Assets
43.3M
↑ 12.38%
Total Liabilities
11.4M
↓ 10.63%
FY19Y/Y Change
Total Assets
45.2M
↑ 4.43%
Total Liabilities
7.5M
↓ 33.82%
FY20Y/Y Change
Total Assets
168.4M
↑ 272.64%
Total Liabilities
12.4M
↑ 64.81%
FY21Y/Y Change
Total Assets
180.0M
↑ 6.86%
Total Liabilities
14.2M
↑ 14.62%
FY22Y/Y Change
Total Assets
188.4M
↑ 4.67%
Total Liabilities
10.1M
↓ 28.61%
FY23Y/Y Change
Total Assets
186.1M
↓ 1.21%
Total Liabilities
16.1M
↑ 58.59%
Q4 FY22Q/Q Change
Total Assets
190.5M
↑ 1.1%
Total Liabilities
10.3M
↑ 2.02%
Q1 FY23Q/Q Change
Total Assets
173.2M
↓ 9.06%
Total Liabilities
8.6M
↓ 16.74%
Q2 FY23Q/Q Change
Total Assets
179.1M
↑ 3.43%
Total Liabilities
9.7M
↑ 13.2%
Q3 FY23Q/Q Change
Total Assets
186.1M
↑ 3.89%
Total Liabilities
16.1M
↑ 64.94%
Q4 FY23Q/Q Change
Total Assets
185.8M
↓ 0.17%
Total Liabilities
13.4M
↓ 16.39%
Q1 FY24Q/Q Change
Total Assets
194.0M
↑ 4.41%
Total Liabilities
16.9M
↑ 26.03%
FY18Y/Y Change
Operating Cash Flow
9.3M
↑ 35.03%
Investing Cash Flow
-2.3M
↓ 46.53%
Financing Cash Flow
-3.8M
↓ 12.99%
FY19Y/Y Change
Operating Cash Flow
11.6M
↑ 25.32%
Investing Cash Flow
-2.0M
↓ 16.02%
Financing Cash Flow
-7.6M
↑ 102.67%
FY20Y/Y Change
Operating Cash Flow
10.9M
↓ 6.24%
Investing Cash Flow
-75.5M
↑ 3760.72%
Financing Cash Flow
102.4M
↓ 1438.48%
FY21Y/Y Change
Operating Cash Flow
19.2M
↑ 75.98%
Investing Cash Flow
-26.7M
↓ 64.58%
Financing Cash Flow
-4.7M
↓ 104.58%
FY22Y/Y Change
Operating Cash Flow
17.9M
↓ 6.79%
Investing Cash Flow
4.3M
↓ 116.1%
Financing Cash Flow
-7.6M
↑ 62.72%
Q4 FY22Q/Q Change
Operating Cash Flow
4.7M
↓ 40.62%
Investing Cash Flow
-6.4M
↓ 378.85%
Financing Cash Flow
-460.0K
↓ 54.72%
Q1 FY23Q/Q Change
Operating Cash Flow
5.5M
↑ 17.72%
Investing Cash Flow
5.3M
↓ 183.29%
Financing Cash Flow
-21.0M
↑ 4463.04%
Q2 FY23Q/Q Change
Operating Cash Flow
8.5M
↑ 54.27%
Investing Cash Flow
7.9M
↑ 48.05%
Financing Cash Flow
-628.0K
↓ 97.01%

Technicals Summary

Sell

Neutral

Buy

Simulations Plus, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Simulations Plus, Inc.
Simulations Plus, Inc.
6.86%
13.39%
5.42%
-28.49%
99.2%
Solventum Corp
Solventum Corp
-10.64%
-10.64%
-10.64%
-10.64%
-10.64%
Veeva Systems Inc.
Veeva Systems Inc.
-12.8%
-3.39%
8.83%
-26.33%
55.83%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-5.98%
30.6%
1.83%
40.83%
40.83%
Healthequity Inc
Healthequity Inc
-3.72%
6.22%
37.05%
12.91%
23.47%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Simulations Plus, Inc.
Simulations Plus, Inc.
87.23
87.23
9.77
0.66
0.06
0.04
0.01
8.86
Solventum Corp
Solventum Corp
NA
NA
NA
0.0
0.12
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
62.03
62.03
1.35
4.76
0.13
0.05
NA
28.8
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
28.08
28.08
20.11
4.3
0.19
0.06
0.0
15.67
Healthequity Inc
Healthequity Inc
125.42
125.42
2.29
2.19
0.03
0.03
NA
23.63
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Simulations Plus, Inc.
Simulations Plus, Inc.
Buy
$906.5M
99.2%
87.23
16.26%
Solventum Corp
Solventum Corp
NA
$11.7B
-10.64%
NA
16.42%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$32.3B
55.83%
62.03
22.24%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$39.0B
40.83%
28.08
8.02%
Healthequity Inc
Healthequity Inc
Buy
$6.9B
23.47%
125.42
5.57%

Institutional Holdings

  • BlackRock Inc

    12.73%
  • Conestoga Capital Advisors, LLC

    11.31%
  • Neuberger Berman Group LLC

    6.61%
  • Vanguard Group Inc

    5.62%
  • Ranger Investment Management LP

    4.66%
  • State Street Corporation

    3.01%

Corporate Announcements

  • Simulations Plus, Inc. Dividends March,2024

    In the quarter ending March,2024. Simulations Plus, Inc. has declared dividend of $0.06

    Read More

Company Information

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res

Organization
Simulations Plus, Inc.
Employees
192
CEO
Dr. Walter S. Woltosz M.A.S., M.S.
Industry
Technology Services

FAQs